ArticleTheranostics2017
PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 78 citations in OpenAlex.
- Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics.Nanomaterials (Basel, Switzerland) · 2026Article
- Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.Pharmaceutics · 2026Article
- Cell membrane biomimetic nanoplatforms: a new strategy for immune escape and precision targeted therapy.Materials today. Bio · 2025Review
- Primary Cilia Formation Mediated by Hsa_Circ_0005185/OTUB1/RAB8A Complex Inhibits Prostate Cancer Progression by Suppressing Hedgehog Signaling Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting AURKA with multifunctional nanoparticles in CRPC therapy.Journal of nanobiotechnology · 2024Article
- A pan-cancer dye for solid-tumour screening, resection and wound monitoring via short-wave and near-infrared fluorescence imaging.Nature biomedical engineering · 2024Article
- Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.Molecular therapy. Nucleic acids · 2024Article
- Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.International journal of molecular sciences · 2024Article
- Design of Chitosan-Coated, Quercetin-Loaded PLGA Nanoparticles for Enhanced PSMA-Specific Activity on LnCap Prostate Cancer Cells.Biomedicines · 2023Article
- D2B-Functionalized Gold Nanoparticles: Promising Vehicles for Targeted Drug Delivery to Prostate Cancer.ACS applied bio materials · 2023Article
- Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.Frontiers in immunology · 2023Review
- Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.ACS applied materials & interfaces · 2022Article
- PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.International journal of molecular sciences · 2022Review
- The TRiCky Business of Protein Folding in Health and Disease.Frontiers in cell and developmental biology · 2022Review
- Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer.Geburtshilfe und Frauenheilkunde · 2022Article
- Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood.PloS one · 2022Article
- Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma.Frontiers in oncology · 2022Article
- Characterization of Proteins Regulated by Androgen and Protein Kinase a Signaling in VCaP Prostate Cancer Cells.Biomedicines · 2021Article
- The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers.Nanomaterials (Basel, Switzerland) · 2021Review
- A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Herein, we report the use of a theranostic nanocarrier (Folate-HBPE(CT20p)) to deliver a therapeutic peptide to prostate cancer tumors that express PSMA (folate hydrolase 1). The therapeutic peptide (CT20p) targets and inhibits the chaperonin-containing TCP-1 (CCT) protein-folding complex, is selectively cytotoxic to cancer cells, and is non-toxic to normal tissue. With the delivery of CT20p to prostate cancer cells via PSMA, a dual level of cancer specificity is achieved: (1) selective targeting to PSMA-expressing prostate tumors, and (2) specific cytotoxicity to cancer cells with minimal toxicity to normal cells. The PSMA-targeting theranostic nanocarrier can image PSMA-expressing cells and tumors when a near infrared dye is used as cargo. Meanwhile, it can be used to treat PSMA-expressing tumors when a therapeutic, such as the CT20p peptide, is encapsulated within the nanocarrier. Even when these PSMA-targeting nanocarriers are taken up by macrophages, minimal cell death is observed in these cells, in contrast with doxorubicin-based therapeutics that result in significant macrophage death. Incubation of PSMA-expressing prostate cancer cells with the Folate-HBPE(CT20p) nanocarriers induces considerable changes in cell morphology, reduction in the levels of integrin β1, and lower cell adhesion, eventually resulting in cell death. These results are relevant as integrin β1 plays a key role in prostate cancer invasion and metastatic potential. In addition, the use of the developed PSMA-targeting nanocarrier facilitates the selective
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.